Know Cancer

forgot password

Phase II Trial of Sunitinib in Bronchoalveolar Carcinoma or Never-Smokers With Any Lung Adenocarcinoma

Phase 2
18 Years
Not Enrolling
Lung Cancer, Adenocarcinoma

Thank you

Trial Information

Phase II Trial of Sunitinib in Bronchoalveolar Carcinoma or Never-Smokers With Any Lung Adenocarcinoma

To participate in this study, patients must have disease that can be measured on a CT scan.
Brain metastases are OK if stable. Pregnant and/or nursing women may not participate. This
drug has been approved by the FDA for the treatment of advanced renal cell cancer and a
certain type of stomach/intestinal cancer. Its efficacy in lung cancer in currently unknown.
Common side effects include fatigue, nausea, diarrhea, skin reaction, and decreased blood

Inclusion Criteria:

- Bronchoalveolar carcinoma with disease measurable on CAT scan

- Any lung adenocarcinoma in a never-smoker (less than 100 cigarettes lifetime) with
disease measurable on CAT scan

- Stage IIIB or IV

Exclusion Criteria:

- Uncontrolled hypertension

- Unstable brain metastases

- Pregnant/nursing women

- Uncontrolled thyroid disease

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-Free Survival

Outcome Time Frame:

January 2009

Safety Issue:


Principal Investigator

Howard West, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Swedish Cancer Institute


United States: Food and Drug Administration

Study ID:

CRC 05160



Start Date:

January 2007

Completion Date:

October 2010

Related Keywords:

  • Lung Cancer
  • Adenocarcinoma
  • bronchoalveolar carcinoma
  • BAC
  • adenocarcinoma
  • lung cancer
  • oral
  • Stage IIIB and IV lung cancer
  • Any bronchoalveolar carcinoma (BAC)
  • Any adenocarcinoma in a never-smoker
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Adenocarcinoma, Bronchiolo-Alveolar
  • Lung Neoplasms



Swedish Cancer Institute Seattle, Washington  98104